Clinical trials: Schizophrenia Spectrum
Schizophrenia, Schizoaffective Disorder
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
- Trial name
- NCT02636842
- Testing
- Aripiprazole Lauroxil
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral administration of different doses in healthy Chinese subjects.
- Trial name
- NCT02174510
- Testing
- 20mg lurasidone, 40mg lurasidone, 80mg lurasidone
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
Pediatric Schizophrenia Efficacy and Safety Study
Efficacy and Safety study of Lurasidone in pediatric patients.
- Trial name
- NCT01911429
- Testing
- Lurasidone 40 mg, Lurasidone 80 mg
- Where
- 90 sites in United States, Belgium and 15 more
- Volunteers
- 327 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of 3 fixed doses of JNJ-37822681 compared with placebo (an inactive substance that is compared with a drug to test if the drug has a real effect in a clinical…
- Trial name
- NCT00728195
- Testing
- JNJ-37822681, Olanzapine
- Where
- 45 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 498 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
Primary Objective: To assess the relative bioavailability of RBP-7000 formulated with 2 different molecular weights (MW) (low and high MW as test treatments) of poly (DL-lactide-co-glycolide) with a carboxylic acid end group…
- Trial name
- NCT02687984
- Testing
- RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Indivior Inc.
Schizophrenia
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
The purpose of this study is to examine whether olanzapine, compared to risperidone, can provide more adequate and timely control of behavioral agitation in acutely ill subjects with schizophrenia.
- Trial name
- NCT00485498
- Testing
- Olanzapine Hydrochloride, Risperidone
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013).
- Trial name
- NCT05211947
- Testing
- Iclepertin
- Where
- 303 sites in United States, Argentina and 38 more
- Volunteers
- 1,356 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Bipolar Disorder
Physician Survey on Monitoring of Patients Treated With Quetiapine
A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01795326
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Bipolar I Disorder, Schizophrenia
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
- Trial name
- NCT04127058
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.
A 12-Month Observational Prospective Multicentre Cohort Study based on existing and newly collected data of schizophrenia patients followed-up for one year in secondary care settings (psychiatric services).
- Trial name
- RESPECT (NCT04742413)
- Where
- 10 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Angelini Farmacéutica
Schizophrenia
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal…
- Trial name
- NCT00645515
- Testing
- Ziprasidone, Risperidone
- Where
- 3 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
SPECT Study With SB-773812 In Schizophrenic Patients
This study is being conducted in 2 groups of schizophrenic patients: in group 1 the relationship between the dopaminergic D2 receptor occupancy (D2 RO ) and serotoninergic 5HT2A receptor occupancy at stable plasma concentration…
- Trial name
- NCT00269035
- Testing
- SB773812, Risperidone
- Where
- 6 sites in Spain
- Volunteers
- 95 people
- Sponsor
- GlaxoSmithKline
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Schizophrenia
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
- Trial name
- NCT01009060
- Testing
- GSK239512
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
This is an extension study to further test the efficacy and safety of asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of schizophrenia.
- Trial name
- NCT00265343
- Testing
- asenapine, olanzapine
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Schizophrenia
A Phase 1 Safety Study in Adults With Schizophrenia
This study will determine the safety, tolerability, and pharmacokinetics (PK) of olanzapine and samidorphan in adults with schizophrenia following 14 consecutive days of oral administration of ALKS 3831.
- Trial name
- NCT02804568
- Testing
- ALKS 3831
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Alkermes, Inc.
Healthy
Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00620568
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer